SCHEMBL1747248

SCHEMBL1747248

COC(=O)CCc1ccc(OC2CCc3cc(OC)ccc32)cc1

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 4/20 0.44
GRIN1 Q05586 1/20 0.44
ALDH1A1 P00352 2/20 0.43
MAPT P10636 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
F2RL1 P55085 1/20 0.43
PPARD Q03181 3/20 0.42
FFAR1 O14842 2/20 0.42
POLB P06746 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MTNR1A P48039 1/20 0.41
VDR P11473 1/20 0.41
CCR2 P41597 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1744984 0.92 MTNR1A (0.50) MTNR1A
SCHEMBL1747100 0.91 FFAR1 (0.45) ALDH1A1MAPTTDP1F2RL1FFAR1
SCHEMBL1745539 0.90 FFAR1 (0.40) ALDH1A1MAPTTDP1PPARDFFAR1
SCHEMBL1747318 0.90 FFAR1 (0.48) GRIN2BGRIN1PPARDFFAR1POLB
SCHEMBL1744781 0.89 FFAR4 (0.44) FFAR1
SCHEMBL1746743 0.89 KDM5A (0.40) FFAR1MEN1KMT2ACCR2
SCHEMBL1744547 0.89 IDO1 (0.41) FFAR1CCR2
SCHEMBL1745269 0.89 KMT2A (0.46) MEN1KMT2AMTNR1A
SCHEMBL1744736 0.88 FFAR1 (0.44) GRIN2BGRIN1TDP1PPARDFFAR1
SCHEMBL15679161 0.87 HRH3 (0.40) ALDH1A1F2RL1PPARDFFAR1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR GRIN2B 1276/4885GRIN1 829/4885ALDH1A1 4258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.